Virtual ligand screening is a powerful technique to identify potential hits of targets and to increase hit rates. Here, we describe how we used this technique combined with NMR 15 N HSQC experiments to obtain small molecules that bind to the PDZ domain of Dvl targeting the Wnt signaling pathway.
Introduction

Structure-Based Virtual Ligand
Screening for Inhibitor of the Dvl PDZ Domain molecule (NSC668036) from the National Cancer Institute (NCI) small-molecule library that can bind to the mDvl1 PDZ domain. Further NMR experiments con fi rmed that the compound binds to the peptide-binding site on the surface of the PDZ domain. In addition, we carried out molecular dynamics (MD) simulations of the interaction between this compound and the PDZ domain as well as that between the C-terminal region of a known PDZ domain inhibitor (Dapper) and the PDZ domain, and we compared the binding free energies of these interactions calculated via the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) method (7) (8) (9) .
With the advancement of technology in the fi eld of drug discovery, hits of a potential therapeutic reagent can be identi fi ed in a comparatively straightforward fashion by using high-throughput screening ( 10, 11 ) . However the follow-up hit-to-lead process and lead optimization still remain as challenging problems in the drug discovery process ( 12, 13 ) . One of the most frequently taken approaches in the hit-to-lead process is hit evolution ( 13 ) . During hit evolution, analogues of the most promising hits are synthesized for the development of structure-activity relationship (SAR) data. The SAR is then used to guide the synthesis and optimization of lead compounds to improve their potencies and physicochemical properties, and to reduce off-target activities. The synthesis processes are usually long and labor intensive. Virtual screening of databases consisting of physically available compounds may help us to take advantage of the chemistry that has already been done and speed up projects, especially with the ever-growing list of existing compounds. Indeed, the Zinc database has 13 million compounds ( 14 ) and the iResearch™ Library (ChemNavigator, San Diego, CA) has more than 50 million unique chemicals. Although the databases of available compounds are still under-sampled ( 15 ) , the chemical space represented by those millions of compounds should never be neglected. We believed that the large chemical space of available compounds offers us with an opportunity to explore SAR of known hits; and as a proof of principle test, we searched the ChemDiv database for the Dvl PDZ domain inhibitors based on an inhibitor identi fi ed above ( 16 ) . In our studies, we fi rst developed a pharmacophore model based on NSC668036; based on the model, we then screened the ChemDiv database by using an algorithm that combines similarity search and docking procedures; fi nally, we selected potent inhibitors based on docking analysis and examined them by using NMR spectroscopy. NMR experiments showed that all the 15 compounds we chose bound to the PDZ domain tighter than NSC668036. UNITY considers the fl exibility of compounds, and it uses the Directed Tweak algorithm to conduct a rapid and conformationally fl exible 3D search ( 18 ) . The search yielded 108 organic compounds as the initial hits.
3. These 108 hits then were "docked" into the binding site of the PDZ domain by using the FlexX program of SYBYL. FlexX is energy minimization modeling software that varies the conformation of the ligand to fi t it into the protein-binding site ( 19 ) . The receptor's binding site was de fi ned by residues Gly266, Ile269, and Arg325 with a selection radius of 5.9 Å, and a core subpocket was de fi ned by Gly266 with a selection radius of 5.9 Å (Fig. 1 ). The docking condition was validated by docking the dapper peptide to the PDZ domain as in Note 2 .
4. The results of the docking procedure were evaluated manually and those compounds that were not docked into the binding pocket of the PDZ domain were removed. The Cscore program of SYBYL was then used to rank the remaining compounds on the basis of their predicted ability to bind to the binding pocket. Cscore generates a relative, consensus score, based on the individual scoring functions of the protein-ligand complex ( 20 ) . One of the scoring functions in Cscore, the 5. Calculating K D by using HSQC titration spectra: The binding af fi nities ( K D ) of PDZ ligands were calculated using HSQC spectra by following the method described by Worrall et al. ( 24 ) . The mean chemical-shift perturbation changes caused by the binding of ligands were calculated using Eq. 1. K D was then calculated using Eqs. 2 and 3 by applying a one-site binding model with corrections for dilutions, where R was the ligand-to-protein molar ratio, P was the protein concentration before titration, C was the ligand stock concentration, and K D was the dissociation constant. Two-parameter nonlinear leastsquares fi tting was performed with program Prism (GraphPad Software, La Jolla, CA):
Testing VLS Hits with NMR Spectroscopy
To further investigate the interaction between the PDZ domain and NSC668036, the AMBER software ( 25 ) suite was used to conduct an MD simulation study of the NSC668036-PDZ domain complex.
1. The starting structures of ligand-protein complexes were prepared using the output from the FlexX docking studies. To sample suf fi cient possible binding modes during the MD simulation, the entire output of the initial FlexX docking results was reexamined. Based on structure alignment, the 30 docked NSC668036 conformers can be grouped into three clusters. Manual inspection of these docking conformers led us to select 10 conformers from the three clusters representing the 30 conformers as starting points for the MD simulations.
2. After neutralization of these complexes with Na + or Cl − , they were dissolved in a periodic rectangular TIP3P water box, with each side 10 Å from the edge of the complex. AM1-BCC charges and parameters from GAFF force fi eld were assigned to NSC668036 by using the Antechamber module ( 26 ) in AMBER 8. For protein, ions, and water, parm99 force fi eld ( 25, 27 ) was used.
3. Systems were minimized by a 1,000-step steepest descent minimization followed by a 9,000-step conjugated gradient minimization ( 25, 27 ) .
4. MD simulation was performed by using the sander program in AMBER 8 with a time step of 2 fs and the nonbonded cutoff set to 9.0 Å. Constant volume (NVT) and constant pressure (NPT) ensemble simulations were carried out to equilibrate the system. In detail, a 50 ps NVT simulation was used to increase the temperature from 100 to 300 K; then the 50 ps NPT ensemble was used to adjust the solvent density, and another 100 ps NPT ensemble was used to gradually reduce the harmonic restraints from 5.0 kcal/mol/Å 2 to none ( 25, 27 ) .
5. MD simulations were performed in explicit water for 5 ns after equilibration with the particle mesh Ewald (PME) method ( 28, 29 ) using the NPT ensemble. During the production run, snapshots were saved every 5 ps. Other simulation parameters were set to values similar to those described in the work by Gohlke et al. ( 30 ) .
Molecular Dynamics Simulation of Veri fi ed PDZ Ligand
1. The MM-PBSA algorithm ( 7-9 ) was then used to calculate the binding free energy of the interaction between the PDZ domain and NSC668036 using Eq. 4 with the mm_pbsa.pl script in AMBER 8, which employs an MM-PBSA approach: 
where the gas phase energy, H gas , is the sum of internal (bond, angle, and torsion), van der Waals, and electrostatic energies in the molecular mechanical force fi eld with no cutoff, as calculated by molecular mechanics ( 31 ) . H trans/rot is 3 RT ( R being the gas constant) because of six translational and rotational degrees of freedom. The solvation free energy, G solvation , was calculated by using the PB model ( 8, 30, 31 ) . In PB calculations, the polar solvation energy, polar solvation G , was obtained by solving the PB equation with Delphi using parse radius, parm94 charges (for the PDZ domain and the Dapper peptide), and AM1-BCC charges (for the compound). The nonpolar contribution was calculated by Eq. 7. In this equation, A is the solvent accessible area calculated by the Molsurf module in Amber 8 and γ (surface tension) and b (a constant) were 0.00542 kcal/ mol/Å 2 and 0.92 kcal/mol, respectively.
2. All of the energy terms given above were averaged from 150 snapshots extracted every 20 ps, and the entropy TS was estimated by normal-mode analysis using 15 snapshots extracted every 200 ps during the last 3-ns production run.
3. During the 10 MD simulation runs, the simulation that started with conformer 22 had the lowest and most stable binding free energy, suggesting that this conformer represents the true PDZ domain-bound conformation of NSC668036 in solution.
A pharmacophore is composed of functional groups essential and necessary for receptor-ligand binding; without those groups, ligands will no longer bind to receptors and lose their activities ( 32 ) . Pharmacophore-based approaches have been widely used and shown successes in the fi eld of computer-aided drug design ( 33, 34 ) . In order to identify more PDZ domain inhibitors, we took such an approach, derived the pharmacophore of PDZ ligands, and used it to screen for PDZ domain inhibitors in the ChemDiv database.
Binding Free Energy Calculation
Deduction of Pharmacophore Based on a PDZ-Inhibitor
Complex Structure and Two Non-binders 1. The complex structure of NSC668036 and the PDZ domain generated by docking and extensive molecular dynamics simulations was used to build a pharmacophore by using LigandScout (Inte:Ligand, Austria). LigandScout extracts 3D pharmacophores based on complex structures ( 35 ) .
2. The LigandScout pharmacophore model of NSC668036 is consistent with the structural analysis. The carboxyl group contributes three hydrogen-bond acceptors and the isopropyl group contributes a hydrophobic interaction to the pharmacophore.
3. The NSC668036 compound was compared with other compounds that did not bind to the PDZ domain as veri fi ed by NMR experiments. By aligning two non-binders, NSC344681 (((((2-amino-3-hydroxybutanoyl) amino)acetyl)amino)acetic acid) and NSC119132 (methyl 3-((2-amino-3-(aminooxy) propanoyl)amino)-2-((aminooxy) methyl)-3-oxopropanoate) against NSC668036, the differences among these structures that might render NSC344681 and NSC119132 inactive were identi fi ed. NSC334681 does not have a hydrophobic group at the 2-position; and NSC119132 is an ester instead of a free acid. This fi nding strongly suggested that both the carboxyl group and the hydrophobic group next to it were important to the binding and might compose the pharmacophore of PDZ ligands since compounds without them did not bind to the protein.
1. Based on the pharmacophore proposed above, a 2D search to retrieve all the compounds with 2-(3-methylbutanoic acid) groups in the ChemDiv database by using UNITY in SYBYL ® (Tripos, Inc.) was carried out and the search returned 116 hits.
2. To reduce the number of compounds needed to test experimentally and to select ligands with higher potentials to bind to the PDZ domain, the hits were further fi ltered by using FlexX docking and "Cscore" ranking following the procedure described in Subheading 2.3.1 . After manually inspecting topranked compounds, 15 compounds were chosen for further examinations based on the following four criteria: (a) the compounds were docked into the designated binding site, (b) their docking conformations were complementary to those of the PDZ domain, and (c) the docked compounds formed hydrogen-bonds with the β A-β B loop as well as (d) additional hydrogen bonds with the PDZ domain. 4. Structure-based pharmacophore models of these compounds were built using LigandScout as in Subheading 2.3.5 .
5. These 15 compounds are similar in structure but have considerable differences in binding af fi nities, and thus provide an opportunity to study their SAR to gain insights into the molecular determinants of PDZ-ligand binding which might facilitate further ligand optimization. These 15 compounds have similar scaffolds except that some of them have an extra double bond in their scaffold. According to their scaffolds, these compounds can be grouped into two classes and by comparing their structures and binding strengths in the context of docking complex structures and complex structure-based pharmacophore model, the SAR models of these 15 compounds can be built. In turn, the SAR models can be used to guide furthering optimization of PDZ ligands. This difference is consistent with the classic "induce-and-fi t" mechanism, in which, upon the binding of a peptide or a small organic molecule, the binding sites in the PDZ domain undergo conformational change to accommodate the bound ligand. However, this fl exibility cannot be fully explored through a UNITY search and the FlexX docking protocols. Therefore, although the PDZ domain of mouse Dvl was used in the experimental studies, the crystal structure of the PDZ domain of Xenopus Dvl provides a better template for the virtual screening steps. Indeed, the binding free energies calculated from MD simulation of the PDZ domain-NSC668036 and PDZ domainDapper peptide complexes fi t well with the experimental binding data.
Docking Validation
As a control, we also docked the Dapper peptide into the PDZ domain using FlexX. Under this condition, the docked Dapper peptide had a conformation similar to that found in the crystal structure of the complex with a backbone RMSD of 2.04 Å. In particular, the backbone RMSD for the last six C-terminal amino acids is 1.22 Å, indicating that the docking procedure we used was able to dock ligand into the binding site of the PDZ domain with reasonable accuracy.
Compound Handling
To test compounds using NMR experiments, they should be dissolved in the same buffer as in which the protein was dissolved. pH should be adjusted back to 7.5 if changed to ensure that perturbations on the PDZ domain would only come from the compounds but not from changes in the condition. For compounds with small solubility in the protein buffer, small amount of DMSO was added so that there would be no more than 5%
Notes
of DMSO in the fi nal mixture of the PDZ domain with the compound. NMR experiments showed that <5% DMSO does not change the spectra of the PDZ domain. Compound solutions were stored in the freezer at −20°C to avoid hydrolysis and/or other reactions that might change compound identities.
Test Selectivity of Identi fi ed Ligands
We tested two other PDZ domains: the fi rst PDZ domain of PSD-95, PSD95a ( 37 ) (PDB entries 1IU0 and 1IU2), which belongs to the class I PDZ domains, and the PDZ7 domain of the glutamate receptor-interacting protein ( 38 ) (PDB entry 1M5Z), a member of the class II PDZ domains. NSC668036 binds to both of these PDZ domains extremely weakly.
